KTTA - Pasithea stock rises on contract with WuXi to make PAS-004

• Pasithea Therapeutics ( NASDAQ: KTTA ) signed a contract with WuXi STA to manufacture the active pharmaceutical ingredient (API) for Pasithea's PAS-004.
• Pasithea plans to start a phase 1 trial of PAS-004 (formerly CIP-137401) in the U.S. to treat Neurofibromatosis type 1 (NF1) — a genetic condition which cause tumors, generally benign, to form on nerve tissue. The condition also causes light or brown patches to appear on the skin.
• WuXi STA, a unit of WuXi AppTec ( OTCPK:WUXAY ) ( OTCPK:WUXIF ), provides chemistry, manufacturing, and controls (CMC) services, for both API and finished dosage forms.
• "PAS-004 has already received orphan drug designation from the FDA for neurofibromatosis 1, and we plan to start our phase 1 clinical trial in the second half of 2023," said Pasithea's Chief Development Officer Graeme Currie.
• KTTA +6.91% to $0.77 premarket Jan. 18

For further details see: